Press
Releases
Press Releases
AVROBIO to Share Comprehensive Gaucher Disease Program Update
Webcast on Wednesday, Dec. 7, 2022, at 8 am ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 17, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will host a virtual Gaucher Disease
Nov 17, 2022
AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update
Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis Rare pediatric disease designations received for Gaucher disease and cystinosis investigational gene therapies Comprehensive Gaucher disease program update planned for Wednesday, Dec. 7 CAMBRIDGE, Mass.
Nov 08, 2022
AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced senior management will be participating in a virtual panel titled “Genomic Medicines – Evolving
Nov 07, 2022
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 3, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 13,000 restricted stock units (RSUs) to two new
Nov 03, 2022
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease
AVR-RD-02 has previously received Fast Track status from FDA, orphan drug designation in the U.S. and EU, and ILAP designation from the U.K. MHRA CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 27, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to
Oct 27, 2022
AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis
First five patients in Phase 1/2 trial show systemic gene therapy effect across multiple tissues evaluated, including eyes, skin, gastrointestinal mucosa and neurocognitive system AVROBIO planning to initiate company-sponsored trial in 2023 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct.
Oct 25, 2022
AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
ILAP intended to accelerate regulatory review process and facilitate patient access in U.K. for seriously debilitating and life-threatening diseases AVR-RD-02 has previously received Fast Track status from U.S. FDA and orphan drug designation in the U.S. and EU CAMBRIDGE, Mass.
Oct 18, 2022
AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development
AVROBIO leading industry in combining use of two safety assays to evaluate genotoxicity risk prior to moving into clinical trials New safety assay uses machine learning algorithms and transcriptional profile data designed to assess the genotoxicity risk of integrating vectors CAMBRIDGE, Mass.
Oct 11, 2022
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 6, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 28,000 restricted stock units (RSUs) to two new
Oct 06, 2022
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 27, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will present new preclinical data on novel assays used to evaluate lentiviral vector
Sep 27, 2022
Displaying 1 - 10 of 36